Current neuroprotective agents in stroke.

Cerebrolysin MLC901 (NeuroAiD II) citicoline neuroprotective stroke.

Journal

Turkish journal of physical medicine and rehabilitation
ISSN: 2587-1250
Titre abrégé: Turk J Phys Med Rehabil
Pays: Turkey
ID NLM: 101719024

Informations de publication

Date de publication:
Jun 2024
Historique:
received: 10 05 2024
accepted: 13 05 2024
medline: 1 7 2024
pubmed: 1 7 2024
entrez: 1 7 2024
Statut: epublish

Résumé

What is expected from neuroprotection is to inhibit neuronal death and halt or decelerate the neuronal loss to lower the mortality rates, decrease disability, and improve the quality of life following an acute ischemic stroke. Several agents were described as neuroprotective up to date; however, there is still debate which to use in the neurorehabilitation of stroke patients, in terms of both efficacy and also safety. In this review, we discuss the agents, citicoline, cerebrolysin and MLC901 (NeuroAiD II), the three agents which have started to be used frequently in neurorehabilitation clinics recently in the light of the current literature.

Identifiants

pubmed: 38948647
doi: 10.5606/tftrd.2024.15287
pmc: PMC11209336
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

157-163

Informations de copyright

Copyright © 2024, Turkish Society of Physical Medicine and Rehabilitation.

Déclaration de conflit d'intérêts

Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Auteurs

Tuğra Yanık (T)

Department of Neurology, Güven Hospital, Ankara, Türkiye.

Burcu Yanık (B)

Department of Physical Medicine and Rehabilitation, Bilkent City Hospital, Ankara, Türkiye.

Classifications MeSH